الفهرس 
Outcome of refractory/relapsing pediatric hodgkin lymphoma at National Cancer Institute
ContentsOnly 14 pages are availabe for public view
 |  | from | 126 |  |  |
| | | from | 126 | | |
Abstract
Purpose: Hodgkin lymphoma constitutes approximately 7% of childhood cancers. Children and adolescents with Hodgkin lymphoma achieve long-term overall survival rates of over 90% with conventional chemotherapy alone or with a combination of chemotherapy and radiotherapy. Nevertheless, up to 10{u2013}15% of low stage and 20{u2013}25% of children with advanced stage HL will relapse or have primary refractory disease. Our aim is to assess the outcome of children and adolescents with relapsing\refractory Hodgkin Lymphoma at the National Cancer Institute-Cairo University. Methods: This is a retrospective analysis over a 7-year period extending from January 2007 to December 2013, which included all patients with relapsing or primary refractory Hodgkin Lymphoma. Results: Thirty-eight patients were included in this study. Twenty-four patients with relapsing HL and 14 with a primary refractory disease. Overall survival rate was worse for primary refractory than relapsing patients (P value = 0.01). Disease stage at relapse was found to be statistically significant for overall survival rate (P value = 0.03). Extranodal involvement have a worse outcome than nodal disease (P value = 0.02). Three year OS rate was 60.7% while 5-year OS rate was 39.4%. Three year and 5-year EFS was 58.9%. There was a significant difference between patients who responded to salvage chemotherapy after 2 cycles and who responded later regarding event free survival rates (P value = 0.03). The age, gender, pathological subtypes and presence of B symptoms at initial diagnosis or at relapse was not found to be statistically significant